



Opportunistic Infections in Hospital Environments: Microbial Resistance and Novel Surveillance and Diagnostic Strategies

Guest Editors:

Dr. Mario Salmeri

Dr. Giuseppe Gattuso

Dr. Cinzia Lombardo

Dr. Maria Lina Mezzatesta

Deadline for manuscript
submissions:
closed (31 July 2022)

Message from the Guest Editors

Healthcare-associated infections (HAIs) may occur in different healthcare wards. A fundamental aspect that has worsened the severity of opportunistic infections is linked to the intensive use of antibiotics. Due to Antimicrobial resistance (AMR), an increase in the number of cases of nosocomial infections for which the most common antibiotic therapies are ineffective has been observed.

The development of novel and effective strategies for the management and monitoring of nosocomial opportunistic infections is of fundamental importance in order to limit the clinical complications of vulnerable patients, especially during this period of health emergency where COVID-19 patients hospitalized in intensive care units may be more susceptible to the development of these nosocomial infections often responsible for fatal outcomes.

On these bases, the aim of this Special Issue is to collect both original articles and review articles describing the latest findings on diagnostic and surveillance strategies for the monitoring of nosocomial opportunistic infections as well as studies aimed at shedding light on novel emerging pathogens or AMR systems.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi